QUÉBEC CITY, March 5, 2015 /CNW
Telbec/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ)
(the "Company") today announced that it has commenced an
underwritten public offering (the "Offering") of units (the
"Units"). Units will consist of common shares, Series A warrants to
purchase common shares (the "Series A Warrants") and Series B
warrants to purchase common shares (the "Series B Warrants").
Investors whose purchase of Units in the Offering would result in
them beneficially owning more than the initial beneficial ownership
limitation to be included in the Warrants following the
consummation of the Offering will have the opportunity to acquire
Units with Series C pre-funded warrants substituted for any common
shares they would have otherwise acquired over the initial
beneficial ownership limitation, paying the same price per Unit.
The pricing and number of Units as well as the exercise price and
duration of the Series A Warrants and Series B Warrants will be
determined in the course of marketing.
Canaccord Genuity Inc. is acting as sole manager for the
proposed Offering. The proposed Offering is subject to
customary conditions, including the approval of The NASDAQ Stock
Market ("NASDAQ") and the Toronto Stock Exchange ("TSX"), and there
can be no assurance as to whether or when the proposed Offering may
be completed, or as to the actual size or terms of the
Offering. The Company has no intention of listing either
series of Warrants on the NASDAQ or TSX.
The Offering is being conducted pursuant to the Company's
effective shelf registration statement on Form F-10 filed with the
U.S. Securities and Exchange Commission (the "SEC"), its
corresponding Canadian base shelf prospectus and an exemption from
the Autorité des marchés financiers permitting the Company to offer
common shares, warrants and such other securities specified therein
in the United States. The proposed
Offering will be made only by means of a preliminary prospectus
supplement, a final prospectus supplement and the accompanying
short form base shelf prospectus. When available, copies of the
preliminary prospectus supplement, the final prospectus supplement
and the accompanying short form base shelf prospectus may be
obtained upon request by contacting the Syndicate department of
Canaccord Genuity Inc., Attention: Syndicate Department, 99 High
Street, 12th Floor, Boston,
Massachusetts 02110, or by telephone/email at (800)
225-6201/prospectus@canaccordgenuity.com. Electronic copies
of the preliminary prospectus supplement, the final prospectus
supplement and the accompanying short form base shelf prospectus
will also be available free of charge at www.sedar.com and
www.sec.gov, respectively.
This press release does not constitute an offer to sell or
a solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such jurisdiction.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty biopharmaceutical company
engaged in developing and commercializing novel treatments in
oncology, endocrinology and women's health. For more information,
visit www.aezsinc.com.
Forward Looking Statements
This press release contains forward-looking statements made
pursuant to the safe harbor provisions of the US Securities
Litigation Reform Act of 1995. Forward-looking statements involve
known and unknown risks and uncertainties that could cause the
Company's actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue
R&D projects, the successful and timely completion of clinical
studies, the risk that safety and efficacy data from any of our
Phase 3 trials may not coincide with the data analyses from
previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to efficiently commercialize one or more of
its products or product candidates, the ability of the Company to
take advantage of business opportunities in the pharmaceutical
industry, uncertainties related to the regulatory process, the
potential of liability arising from shareholder lawsuits and
general changes in economic conditions. Investors should consult
the Company's quarterly and annual filings with the Canadian and US
securities commissions for additional information on risks and
uncertainties relating to forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The
Company does not undertake to update these forward-looking
statements. We disclaim any obligation to update any such factors
or to publicly announce the result of any revisions to any of the
forward-looking statements contained herein to reflect future
results, events or developments, unless required to do so by a
governmental authority or by applicable law.
SOURCE Aeterna Zentaris Inc.